Puma Biotechnology, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Unless noted otherwise, financial amounts are in millions of dollars. The filing was signed August 3, 2023.
Business context
Puma is a biopharmaceutical company commercializing NERLYNX (neratinib) for certain HER2-positive breast cancers and developing alisertib, licensed from Takeda in 2022. NERLYNX is currently the company’s principal product and is sold directly in the U.S.; international sales are largely through sublicensees. Management intends to develop alisertib initially in small cell lung cancer and hormone receptor-positive breast cancer.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $54.6 | $59.5 | $107.3 | $105.3 |
| Product revenue, net | $51.6 | $51.3 | $98.3 | $92.0 |
| Royalty revenue | $3.0 | $8.2 | $9.0 | $13.2 |
| Operating income | $4.9 | $12.1 | $9.3 | $11.3 |
| Net income | $2.1 | $9.4 | $3.5 | $6.0 |
| Diluted EPS | $0.05 | $0.21 | $0.07 | $0.14 |
| Operating cash flow | Not separately presented for the quarter | $5.9 | $(40.8) |
Q2 gross margin was approximately 78% (74.9% in Q2 2022); six-month gross margin was approximately 77% (75% in 2022), calculated as revenue less cost of sales divided by revenue. Operating margin was approximately 9% in Q2 and 9% for the first half, versus approximately 20% and 11%, respectively, in the comparable 2022 periods.
At June 30, cash and cash equivalents were $60.0, marketable securities $14.4, and working capital $58.3. Cash, cash equivalents and restricted cash totaled $62.6. Total assets were $200.5 and stockholders’ equity $30.4. Long-term debt, net, was $87.6, with $11.3 classified as current; the notes’ principal and exit payment totaled $102.0. The company reported compliance with applicable debt covenants at June 30.
For the first half, investing activities used $22.1, principally $12.5 for a Pfizer-related intangible milestone and $10.5 to purchase available-for-sale securities. Financing activities were nil, and cash, cash equivalents and restricted cash decreased $16.2.
Material changes and management commentary
- Q2 revenue declined $5.0 year over year as royalty revenue fell $5.2, mainly due to timing of sublicensee sales in China; product revenue increased $0.2. First-half revenue rose $2.1 as product revenue increased $6.3, partly offset by a $4.2 royalty decline.
- Management attributed first-half product revenue growth mainly to higher net selling price; NERLYNX bottle sales were comparable with the prior-year period. Q2 bottles sold declined approximately 5.5% year over year.
- Q2 SG&A increased 18.9% to $24.5, reflecting payroll costs, legal and professional fees, and a $0.5 credit-loss provision on a sublicensee royalty receivable. First-half SG&A increased 14.6% to $46.9.
- First-half R&D decreased 4.2% to $26.1, primarily because of lower clinical-trial costs following reduction and closure of SUMMIT trial sites; internal R&D costs increased.
- Interest expense increased to $3.3 in Q2 and $6.6 for the first half, primarily due to higher rates on the Athyrium notes and imputed interest on the remaining Eshelman settlement installment. The notes had a 12.99% effective interest rate at June 30.
Outlook, risks, contingencies and unusual items
- Management stated that cash, cash equivalents and marketable securities, together with anticipated product sales and sublicense payments, were expected to cover operating cash needs for at least one year after filing. The filing also says development, marketing or commercialization efforts may require additional funding and that future financing is not assured.
- The Athyrium notes are secured by substantially all assets, have a July 2026 maturity, and carry minimum cash and product-revenue covenants. Principal payments are scheduled to begin June 2024. A 100-basis-point rate increase would have increased quarterly interest expense by about $1.0.
- On July 7, 2023, the company entered into a limited waiver and fifth amendment to the note purchase agreement. The supplied filing text does not clearly describe the amendment’s terms; verify the exhibit and any effect on covenants or liquidity.
- The $8.0 final installment of the $16.0 Eshelman litigation settlement is due on or before November 1, 2024. Puma re-filed a legal malpractice action in June 2023. A separate putative class action alleges a data-security incident; potential damages are uncertain, and the company believes any amount would be immaterial.
- NERLYNX faces generic-entry and patent-enforcement uncertainty. A Sandoz settlement permits generic sales on or around December 8, 2030, subject to possible adjustment. Chinese generic applications and related patent proceedings remain active; some administrative decisions lifted application stays.
- Takeda may receive up to $287.3 in alisertib regulatory and commercial milestones plus royalties. International sublicense agreements include up to approximately $579.8 in potential milestones to Puma. These contingent amounts are not assured; timing and achievement are not clear from the filing.
- Management cautions that it has a single principal commercial product, relies on third parties to manufacture products and drug candidates, and has incurred significant historical losses. Future results depend on NERLYNX commercialization, alisertib development, regulatory outcomes and access to funding.
No specific numerical revenue or earnings guidance for 2023 is stated in the supplied filing text. Disclosure controls and procedures were assessed as effective as of June 30, 2023.
Important facts for investors to verify
- Read the July 7, 2023 limited waiver and fifth amendment exhibit; confirm covenant status, any waiver conditions and debt implications.
- Assess NERLYNX demand, pricing and bottle trends, and the timing and creditworthiness of sublicensee royalties, particularly China-related receipts.
- Review cash burn, the timing of debt principal payments beginning in 2024, interest-rate exposure, and management’s one-year liquidity assessment.
- Track alisertib clinical-development plans, spending and milestone obligations, and whether additional financing may be required.
- Follow Chinese generic proceedings, the scheduled May 2024 AstraZeneca trial, the Sandoz license terms, and the status and potential exposure of other legal matters.